Published procurement activity · 1,387 tenders
Buyer information published with procurement notices.
Provision of NHS National Framework Agreement for the supply of Intravenous and Irrigation Fluids (Various Strengths & Sizes): Glucose: IV bags and needle-free options. Glucose combinations: IV Bags and needle-free options with sodium chloride, lidocaine, potassium chloride, and plasma/electrolytes. Sodium chloride: IV bags (fle
Project title: NHS National Framework for Transition products (Nilotinib and Ticagrelor) commencing 1st September 2025 Offer reference number: CM/TNS/24/5721 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods
The PCN Test Site programme is a quantitative data gathering exercise to better understand demand and capacity in general practice and to explore solutions to close any gap. Those solutions include additional capacity and the PCNs working on quality improvement (QI) projects. We are looking for experienced facilitators to suppor
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment
Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment
Interested suppliers are asked to complete a Request for Information (RFI) This RFI seeks to improve our understanding about the market and focuses on 4 key areas: 1. UK nutrition market overview 2. UK nutrition market and current commercial model 3. Future market options 4. Implementing change Please note the following general
Organisation details and tender classifications reflect information published by the original procurement sources. Similar buyer names are grouped only where an official identifier or compatible name and postcode provide a safe link.